Formulary guidance and transparency from P&T to point of care


Reality Check on Atopic Dermatitis

Market access for atopic dermatitis treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.  

To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:

  • Payer Insights: Under the pharmacy benefit, about 23% of the lives under commercial formularies are covered with utilization management restrictions
  • Class Trends: In June 2020, the FDA approved a 300 mg single-dose prefilled pen for Regeneron Pharmaceuticals, Inc. and Sanofi’s Dupixent (dupilumab) to treat people at least 12 years old with atopic dermatitis, asthma and chronic rhinosinusitis with nasal polyposis for at-home administration
  • Key Findings: Sanofi and Regeneron’s Dupixent (dupilumab) and Pfizer Inc.’s Eucrisa (crisaborole) are competing for preferred status after topical corticosteroids and topical calcineurin inhibitors and phototherapy. Numerous companies are poised to enter the same market space, many with new biological agents

What can pharma do to curb this trend and overcome these challenges?

Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.

Download the full Reality Check now.